Related Experiment Video

Updated: Jul 16, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Emerging options with coxib therapy

Mark J Lema1

  • 1Department of Anesthesiology, State University of New York at Buffalo School of Medicine, USA. mlema@acsu.buffalo.edu

Cleveland Clinic Journal of Medicine
|June 28, 2002
PubMed

Insights

Cyclooxygenase-2 selective inhibitors (coxibs) show potential beyond arthritis pain relief. Research is exploring their use in Alzheimer's disease treatment and colorectal cancer prevention, with promising preliminary results.

Area of Science:

  • Pharmacology
  • Oncology
  • Neurology

Background:

  • Cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) are currently used for arthritis pain.
  • Inflammatory mechanisms are implicated in Alzheimer's disease (AD) neurodegeneration.
  • Coxibs are being investigated for chemopreventive benefits in colorectal cancer (CRC).

Purpose of the Study:

  • To explore the extended clinical applications of coxibs.
  • To evaluate the efficacy of coxibs in Alzheimer's disease.
  • To assess the chemopreventive potential of coxibs in colorectal cancer.

Main Methods:

  • Review of epidemiological surveys, preclinical studies, and clinical trials.
  • Ongoing clinical trials investigating coxibs' effect on AD progression.
  • Studies on tumor cell lines, animal, and human models for CRC chemoprevention.

Main Results:

  • Preliminary evidence suggests a role for inflammatory mechanisms in AD.
  • Coxibs demonstrate potential to promote apoptosis and inhibit angiogenesis in CRC.
  • Coxibs offer an opioid-sparing effect in cancer pain management without significant adverse effects.

Conclusions:

  • Coxibs may offer therapeutic benefits in Alzheimer's disease.
  • Coxibs show promise as chemopreventive agents for colorectal cancer.
  • Coxibs are valuable in palliative care for cancer pain management.

More Related Videos

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis04:47

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications